6-K
NOVO NORDISK A S (NVO)
6-K
2025-02-06
For: 2025-02-06
View Original
Added on
April 09, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 6, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
|---|
Tradingin Novo Nordisk shares by board members, executives and associated persons
Bagsværd,Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
|---|---|---|---|---|
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Liselotte<br> Sofie Hyveled | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Member<br> of the Board of Directors | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 1,407<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 1,407<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | President<br> and CEO | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 98,702<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 98,702<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | President<br> and CEO | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Sale<br> of shares | ||
| c) | Price(s)<br> and volume(s) | |||
| Volume(s) | ||||
| 32<br> shares | ||||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 32 shares<br> 19,779<br> DKK | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | AQUIS<br> EXCHANGE OPE NON DISPLAY ORDER BOOK (NDOB) |
All values are in Euros.
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 |
|---|---|---|---|
| Company announcement No 8 / 2025 | |||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | ||
| --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | |
| 2 | Reason<br> for the notification | ||
| a) | Position/status | President<br> and CEO | |
| b) | Initial<br> notification/Amendment | Initial<br> notification | |
| 3 | Details<br> of the issuer | ||
| a) | Name | Novo<br> Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details<br> of the transaction(s) | ||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | |
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | ||
| b) | Nature<br> of the transaction | Sale<br> of shares | |
| c) | Price(s)<br> and volume(s) | ||
| Volume(s) | |||
| 1,104<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 1,104<br> shares<br> 683,905<br> DKK | |
| e) | Date<br> of the transaction | 2025-02-05 | |
| f) | Place<br> of the transaction | AQUIS<br> EXCHANGE OPE |
All values are in Euros.
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 |
|---|---|---|---|
| Company announcement No 8 / 2025 | |||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | ||
| --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | |
| 2 | Reason<br> for the notification | ||
| a) | Position/status | President<br> and CEO | |
| b) | Initial<br> notification/Amendment | Initial<br> notification | |
| 3 | Details<br> of the issuer | ||
| a) | Name | Novo<br> Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details<br> of the transaction(s) | ||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | |
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | ||
| b) | Nature<br> of the transaction | Sale<br> of shares | |
| c) | Price(s)<br> and volume(s) | ||
| Volume(s) | |||
| 978<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 978<br> shares<br> 603,976<br> DKK | |
| e) | Date<br> of the transaction | 2025-02-05 | |
| f) | Place<br> of the transaction | CBOE<br> OPE - DXE PERIODIC (NL) |
All values are in Euros.
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 |
|---|---|---|---|
| Company announcement No 8 / 2025 | |||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | ||
| --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | |
| 2 | Reason<br> for the notification | ||
| a) | Position/status | President<br> and CEO | |
| b) | Initial<br> notification/Amendment | Initial<br> notification | |
| 3 | Details<br> of the issuer | ||
| a) | Name | Novo<br> Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details<br> of the transaction(s) | ||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | |
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | ||
| b) | Nature<br> of the transaction | Sale<br> of shares | |
| c) | Price(s)<br> and volume(s) | ||
| Volume(s) | |||
| 42<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 42 shares<br> 26,083<br> DKK | |
| e) | Date<br> of the transaction | 2025-02-05 | |
| f) | Place<br> of the transaction | CBOE<br> OPE - DXE DARK ORDER BOOK (NL) |
All values are in Euros.
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 |
|---|---|---|---|
| Company announcement No 8 / 2025 | |||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | ||
| --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | |
| 2 | Reason<br> for the notification | ||
| a) | Position/status | President<br> and CEO | |
| b) | Initial<br> notification/Amendment | Initial<br> notification | |
| 3 | Details<br> of the issuer | ||
| a) | Name | Novo<br> Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details<br> of the transaction(s) | ||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | |
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | ||
| b) | Nature<br> of the transaction | Sale<br> of shares | |
| c) | Price(s)<br> and volume(s) | ||
| Volume(s) | |||
| 8,331<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 8,331<br> shares<br> 5,149,984<br> DKK | |
| e) | Date<br> of the transaction | 2025-02-05 | |
| f) | Place<br> of the transaction | CBOE<br> OPE - DXE ORDER BOOKS (NL) |
All values are in Euros.
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 |
|---|---|---|---|
| Company announcement No 8 / 2025 | |||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | ||
| --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | |
| 2 | Reason<br> for the notification | ||
| a) | Position/status | President<br> and CEO | |
| b) | Initial<br> notification/Amendment | Initial<br> notification | |
| 3 | Details<br> of the issuer | ||
| a) | Name | Novo<br> Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details<br> of the transaction(s) | ||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | |
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | ||
| b) | Nature<br> of the transaction | Sale<br> of shares | |
| c) | Price(s)<br> and volume(s) | ||
| Volume(s) | |||
| 1,577<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 1,577<br> shares<br> 974,805<br> DKK | |
| e) | Date<br> of the transaction | 2025-02-05 | |
| f) | Place<br> of the transaction | TURQUOISE<br> OPE |
All values are in Euros.
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
|---|---|---|---|---|
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Lars<br> Fruergaard Jørgensen | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | President<br> and CEO | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Sale<br> of shares | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| 618.88<br> DKK | 22,936<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 22,936<br> shares<br><br> <br>14,194,575<br> DKK | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | NASDAQ<br> COPENHAGEN A/S | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Maziar<br> Mike Doustdar | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 36,956<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 36,956<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Maziar<br> Mike Doustdar | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Sale<br> of shares | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 614.55 | 1,852<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 1,852<br> shares<br><br> <br>DKK<br> 1,138,154 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Nasdaq<br> Copenhagen | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Ludovic<br> Helfgott | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 27,765<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 27,765<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Ludovic<br> Helfgott | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Sale<br> of shares | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 614.55 | 8,990<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 8,990<br> shares<br><br> <br>DKK<br> 5,524,840 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Nasdaq<br> Copenhagen | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Ludovic<br> Helfgott | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Sale<br> of shares | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 617.00 | 12,000<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 12,000<br> shares<br><br> <br>DKK<br> 7,404,000 | ||
| e) | Date<br> of the transaction | 2025-02-06 | ||
| f) | Place<br> of the transaction | Nasdaq<br> Copenhagen | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Karsten<br> Munk Knudsen | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 30,728<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 30,728<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Martin<br> Holst Lange | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 30,728<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 30,728<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Tania<br> Sabroe | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 10,561<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 10,561<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Marcus<br> Schindler | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 30,728<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 30,728<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Camilla<br> Sylvest | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 30,728<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 30,728<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Camilla<br> Sylvest | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Sale<br> of shares | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 615.00 | 15,364<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 15.364<br> shares<br><br> <br>DKK<br> 9,448,860 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Nasdaq<br> Copenhagen | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 | ||||
| 1 | Details<br> of the person discharging managerial responsibilities/person closely associated | |||
| --- | --- | --- | --- | --- |
| a) | Name<br> of the Board member/Executive/Associated Person | Henrik<br> Ehlers Wulff | ||
| 2 | Reason<br> for the notification | |||
| a) | Position/status | Executive<br> Vice President | ||
| b) | Initial<br> notification/Amendment | Initial<br> notification | ||
| 3 | Details<br> of the issuer | |||
| a) | Name | Novo<br> Nordisk A/S | ||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||
| 4 | Details<br> of the transaction(s) | |||
| a) | Description<br> of the financial instrument,<br><br> <br>type<br> of instrument, | Shares | ||
| Identification<br> code | Novo<br> Nordisk B DK0062498333 | |||
| b) | Nature<br> of the transaction | Other<br> transaction (transfer of shares in<br><br> <br>accordance<br> with Long Term Incentive programme) | ||
| c) | Price(s)<br> and volume(s) | |||
| Price(s) | Volume(s) | |||
| DKK<br> 0.00 | 32,448<br> shares | |||
| d) | Aggregated<br> information<br><br> <br>· <br> Aggregated volume<br><br> <br>· <br> Price | 32,448<br> shares<br><br> <br>DKK<br> 0.00 | ||
| e) | Date<br> of the transaction | 2025-02-05 | ||
| f) | Place<br> of the transaction | Outside<br> a trading venue | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 | |
| --- | --- | --- | --- | |
| Company announcement No 8 / 2025 |
NovoNordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeatserious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to ourmedicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets itsproducts in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New YorkStock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contactsfor further information
| Media: | **** | ||
|---|---|---|---|
| Ambre James-Brown<br><br> <br>+45 3079 9289<br><br> <br>abmo@novonordisk.com | Liz Skrbkova (US)<br><br> <br>+1 609 917 0632<br><br> <br>lzsk@novonordisk.com | ||
| Investors: | **** | ||
| Jacob Martin Wiborg Rode<br><br> <br>+45 3075 5956<br><br> <br>jrde@novonordisk.com | David Heiberg Landsted<br><br> <br>+45 3077 6915<br><br> <br>dhel@novonordisk.com | ||
| Sina Meyer<br><br> <br>+45 3079 6656<br><br> <br>azey@novonordisk.com | Ida Schaap Melvold<br><br> <br>+45 3077 5649<br><br> <br>idmg@novonordisk.com | ||
| Max Ung<br><br> <br>+45 3077 6414<br><br> <br>mxun@novonordisk.com | Frederik Taylor Pitter<br><br> <br>+1 609 613 0568<br><br> <br>fptr@novonordisk.com | ||
| Novo Nordisk A/S<br><br> <br>Investor Relations | Novo Allé 1<br><br> <br>2880 Bagsværd<br><br> <br>Denmark | Telephone:<br><br> <br>+45 4444 8888 | www.novonordisk.com<br><br> CVR no: 24 25 67 90 |
| --- | --- | --- | --- |
| Company announcement No 8 / 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 6, 2025 | NOVO NORDISK A/S<br><br> <br><br><br> <br>Lars Fruergaard Jørgensen<br><br> <br>Chief Executive Officer |
|---|